VC Firms Avoid Middle Ground When Selecting Device Start-Ups
This article was originally published in The Gray Sheet
Executive Summary
Early- or late-round exit strategies tend to hold the most promise for profitable investments in med tech start-up firms, venture capitalists opined during a panel session at the recent Wilson Sonsini Goodrich & Rosati Medical Device Conference
You may also be interested in...
Advanced Bionics Grab Gives Boston Scientific Neurostim Growth Platforms
Boston Scientific is prepared to pay up to $4 bil. for neuromodulation systems developer Advanced Bionics as a means to add high-growth potential beyond its core vascular intervention business
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.